Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPro-UK in Acute Ischemic Stroke (PROST-2)
NCT05700591Phase 3Completed
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Start
- Jan 2023
- Primary completion
- Mar 2024
- Modality
- Metabolic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of recombinant human prourokinase in ischemic stroke (2 arms), sponsored by Tasly Biopharmaceuticals Co., Ltd. Primary endpoint: Proportion of patients with excellent functional outcome (mRS 0-1) at 90 days. Started Jan 2023; status: completed.
02
Drugs
recombinant human prourokinase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05700591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05700591.